The CRPC trial – KEYNOTE-921 – looked at the combination of Keytruda (pembrolizumab) with docetaxel in more than 1,000 patients who had not been treated with chemotherapy before, but who had seen disease progression despite earlier treatment with an anti-hormonal therapy.
The combination was compared to placebo plus docetaxel in the study, but was unable to show a significant improvement in overall survival (OS) or radiographic progression-free survival (rPFS) – the trial’s two primary endpoints.